INTS 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025

• Research and development expenses during the three months ended March 31, 2026 decreased $1.0 million or 45%, compared to the three months ended March 31, 2025, and was primarily due to the following:

• •INVINCIBLE-3 Study costs decreased $1.1 million. In March 2025, we paused new site activations and patient enrollments in the INVINCIBLE-3 Study due to funding constraints. Prior to this pause, the trial had enrolled 21 patients. We have continued to treat all patients enrolled in this study in coo…

• •Salaries and benefits related costs decreased due to lower headcount in 2026, which was entirely offset by an estimated bonus accrual during the three months ended March 31, 2026 compared to no estimated accrual during the three months ended March 31, 2025.

• •Salaries and benefits related costs increased due to an estimated bonus accrual during the three months ended March 31, 2026 compared to no estimated accrual during the three months ended March 31, 2025, which were partially offset by lower stock-based compensation.

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• Three Months Ended September 30,Nine Months Ended September 30,

• Three Months Ended September 30,Nine Months Ended September 30,

• Three Months Ended September 30,Nine Months Ended September 30,

• Three Months Ended September 30, 2025 Compared to Three Months Ended September 30, 2024

• •Salaries and benefits related costs decreased $0.2 million as we did not accrue current year bonus accruals due to insufficient cash reserves and the current assessment that current year bonus payments are not reasonably probable to occur.

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• Changes to U.S. tariff and import/export regulations may have an adverse effect on our business, financial condition and results of operations.

• There have been significant changes and continue to be ongoing discussion and commentary regarding potential significant changes to U.S. trade policies, treaties and tariffs, creating significant uncertainty about the future relationship between the United States and other countries with respect to …

• We may not satisfy the Nasdaq Capital Market’s requirements for continued listing of our common stock. If we cannot satisfy these requirements, the Nasdaq Capital Market could delist our common stock.

• Our common stock is listed on the Nasdaq Capital Market under the symbol “INTS.” To continue to be listed on the Nasdaq Capital Market, we are required to satisfy a number of conditions. As previously disclosed, on May 19, 2025, we received notice from the staff of the Nasdaq Stock Market that we we…

• We cannot assure you that we will be able to regain and continue compliance with these requirements, which are conditions for continued listing on the Nasdaq Capital Market, or that we will satisfy the Nasdaq Capital Market listing requirements in the future. Our failure to regain compliance with an…